Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-30

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In recent years, knowledge about cancer biology has expanded significantly. The study of gene expression profiles has revealed the heterogeneous nature and potential reclassification of the various tumor subtypes based on specific genetic alterations. This is of great importance since it allows a therapeutic approach more directed to the intrinsic characteristics of each tumor (precision medicine).

Integrating clinicopathological information with molecular classification could provide new guidelines when approaching patients with EC, both in preoperative assessment and in adjuvant treatment and surveillance.

The application of molecular classification in endometrial carcinomas shows a subgroup of patients with an excellent prognosis, corresponding to the POLEmut subgroup that could be reclassified with eventual therapeutic de-escalation.

The clinical guidelines for the management of patients with endometrial cancer proposed by ESGO/ESTRO/ESP in 2020 recommend the use of this new classification, and warn that clinical management may be modified by the molecular classification in scenarios where adjuvant chemotherapy is considered (high-grade/high-risk disease).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis

NCT06206083

Endometrial Cancer

RECRUITING

Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer.

NCT06279832

Endometrial Cancer

RECRUITING NA

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

NCT06893861

Endometrial Carcinoma (EC)

RECRUITING

Predictors of Node Positivity in Endometrial Cancer

NCT05793333

Endometrial Cancer

RECRUITING

Mutational Oncology in Clinical Practice

NCT06020625

Genome Instability Genetic Predisposition to Disease Gene Rearrangement

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Cancer, Endometrial Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years of age with a diagnosis of EC diagnosed by histological biopsy and surgically treated sequentially in the participating centers in the last 5 years with clinical follow-up.
* Patients over 18 years of age, diagnosed with CE III-IV by histological biopsy, not susceptible to surgical treatment in each institution during the last 5 years in clinical follow-up. Cases with a diagnosis of carcinosarcoma (a rare subtype of endometrial carcinoma with sarcomatous transdifferentiation) are included.
* Material blocks fixed in formalin and embedded in paraffin with a tumor volume in the paraffin block of at least 1 cm3

Exclusion Criteria

* The following uterine neoplasms will be excluded:

* Biphasic tumors (epithelial-mesenchymal) such as adenosarcoma.
* Mesenchymal neoplasms such as endometrial stromal sarcoma and leiomyosarcomas.
* Others: primary lymphoproliferative processes of the uterine body; neuroendocrine tumors; Gestational trophoblastic disease, secondary lesions either of the genital tract (example: cervical carcinomas with extension to the endometrium) or of distant sites (breast cancer metastasis).

* Patients with synchronous endometrial and ovarian carcinoma
* For technical reasons, they will be excluded
* tumors smaller than 0.2 cm in which sufficient material cannot be obtained for immunohistochemical and molecular biology determinations.
* Tumors with severe artifacts due to poor processing, such as autolysis.
* Samples with low-quality DNA

* Patients operated on outside participating centers.
* Patients under 18 years of age.
* Patients with primary non-surgical treatments (neoadjuvant chemotherapy).

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No